Skip to Content
Merck
CN

SML4100

Vidofludimus

≥98% (HPLC)

Synonym(s):

IMU-838, 2-((3-Fluoro-3′-methoxy-[1,1′-biphenyl]-4-yl)carbamoyl)cyclopent-1-enecarboxylic acid, 2-[[(3-Fluoro-3′-methoxy[1,1′-biphenyl]-4-yl)amino]carbonyl]-1-cyclopentene-1-carboxylic acid, 2-[[2-Fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid, 4SC-101, IMU 838, IMU838, SC12267

Sign Into View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C20H18FNO4
CAS Number:
717824-30-1
Molecular Weight:
355.36
MDL number:
MFCD18633262

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to yellow

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

SMILES string

Fc1c(ccc(c1)c3cc(ccc3)OC)NC(=O)C2=C(CCC2)C(=O)O

InChI

1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)

InChI key

XPRDUGXOWVXZLL-UHFFFAOYSA-N

Related Categories

Biochem/physiol Actions

Orally active, potent dihydroorotate dehydrogenase (DHODH) inhibitor in cultures and in vivo.
Vidofludimus (4SC-101) is an orally active, potent dihydroorotate dehydrogenase (DHODH) inhibitor (human DHODH IC50 = 134 nM; IC50 = 13 µM against PHA-stimulated lymphocytes proliferation) that inhibits PHA-induced IL-17 secretion from human PBMCs (IC50 = 6 µM) and exhibits therapeutic efficacy in murine models of colitis (50-100 mg/kg/d via intragastric administration; chronic dextran sodium sulfate-induced and acute TNBS-induced colitis) and a rat model of renal transplantation in vivo (20 mg/kg/d p.o.).

Pictograms

Exclamation markEnvironment
GHS07,GHS09

Signal Word

Warning

Hazard Statements

H302,H400

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000397113
0000397112
0000380169
0000380169
0000397112

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Onkar P Kulkarni et al.
The American journal of pathology, 176(6), 2840-2847 (2010-04-24)
Immunosuppressive treatments of systemic lupus (SLE) remain associated with significant toxicities; hence, compounds with better toxicity profiles are needed. Dihydroorotate dehydrogenase (DHODH) inhibition with leflunomide has proven to be effective in autoimmune diseases including SLE, but leflunomide can cause a
Leo R Fitzpatrick et al.
Inflammatory bowel diseases, 16(10), 1763-1777 (2010-03-24)
Dihydroorotate dehydrogenase (DHODH) is a key enzyme involved in pyrimidine biosynthesis. DHODH is a known target for the treatment of autoimmune diseases. 4SC-101 is a novel immunosuppressive drug that inhibits DHODH. A goal of our study was to examine the
Krisztina Rusai et al.
Transplantation, 93(11), 1101-1107 (2012-05-23)
4SC-101 is a novel dihydroorotate dehydrogenase inhibitor and a blocker of interleukin (IL)-17 secretion with beneficial effects in experimental lupus and inflammatory bowel disease. Its immunomodulatory effect on acute kidney rejection is not known; therefore, in this study, the impact

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service